William Blair analyst Robert Napoli downgrades Coupa Software (NASDAQ:COUP) from Outperform to Market Perform.
Preclinical Trial Results Confirm Targeting Type 2 Cannabinoid Receptors Helps Relieve Sepsis-Related Condition
Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1) revealed positive preclinical results from live SARS-CoV-2 virus infection studies as well as a septic lung model, carried out by independent researchers.
